Key result
Preoperative roxadustat shows no difference in adverse events or postoperative complications versus placebo.
Why the study?
Does preoperative roxadustat reduce postoperative complications and demonstrate perioperative tolerability in patients undergoing major elective noncardiac surgery?
RCT (n=150)
Double-blind
randomised-controlled
No
Does preoperative roxadustat reduce postoperative complications and demonstrate perioperative tolerability in patients undergoing major elective noncardiac surgery?
Preoperative administration of roxadustat before major elective noncardiac surgery was feasible with high compliance, though larger trials are required to establish safety and efficacy for reducing postoperative complications.
Answers are grounded in this paper and cite their sources.
Supports perioperative tolerability of preoperative roxadustat; larger trials needed to assess efficacy for postoperative outcomes.
Postoperative complications remain a leading cause of mortality. Experimental data indicate that roxadustat, a first-in-class prolyl hydroxylase inhibitor, reduces ischaemia-reperfusion injury, accelerates wound healing, and enhances survival in sepsis. Therefore, preoperative administration of roxadustat might reduce perioperative organ injury. We examined the perioperative tolerability and the potential for adverse surgical interactions with roxadustat. In this phase 2a, single-centre, double-blind, randomised-controlled pilot trial, 150 patients undergoing major elective noncardiac surgery were allocated to preoperative roxadustat 100 mg or placebo for three alternate-day doses, with the last dose on the operative morning. The co-primary outcomes were preoperative adverse events and postoperative complications meeting standardised endpoint definitions within 30 days. Among 148 participants (52 [35.1%] females; median age 65 [range 24-84] yr) receiving at least one drug dose, at least one preoperative adverse event occurred in 21 of 75 (28%) in the roxadustat group and 20 of 73 (27%) in the placebo group (odds ratio 1.03; 95% CI 0.50-2.12). No serious adverse reactions occurred. Among 143 participants who proceeded to surgery (52 [36.4%] females; median age 65 [range 26-84] yr), ≥1 complication occurred in 23 of 74 participants (31%) who received roxadustat compared with 21 of 69 participants (30%) who received placebo (odds ratio 1.03; 95% CI 0.51-2.10). Days alive out of hospital within 30 days was similar between the groups. The annualised enrolment rate was 90 per year, with high levels of drug compliance. Preoperative roxadustat was feasible in patients having major surgery. Uncertainty remains regarding the safety and efficacy of this intervention. www.anzctr.org.au; ACTRN12624000188538.
No takes yet. Share an insight, caveat, or question.
Toner et al. (2026) conducted an RCT in Major elective noncardiac surgery (n=150). Roxadustat vs. Placebo was evaluated on Co-primary outcomes: preoperative adverse events and postoperative complications meeting standardised endpoint definitions within 30 days (OR 1.03, 95% CI 0.51-2.10). Preoperative roxadustat showed similar rates of preoperative adverse events and 30-day postoperative complications vs placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: